Our Team
Meet the team! This is our senior management and scientific team. We're involved in many different projects across the globe, dedicating the right level of experience and expertise to every client project.
Every day brings us closer to discovering a major breakthrough in the search for new drugs to prevent, alleviate or cure. Mark is passionate about translational biology and the pivotal role it has towards delivering this.
As CEO of well known CRO companies in France and Singapore, he has enjoyed a privileged position in leading and influencing vital drug discovery programmes. Here in the UK, as CEO of Transpharmation, Mark’s work continues in translational biology with innovative science at the core.
Joseph is focused on optimizing the translational value of Transpharmation's services to facilitate the development and approval of novel drugs. Joseph continues to be closely involved in projects utilizing, characterizing and developing the aged dog as a natural model of age-related human diseases.
Joseph is a strong proponent for the use of validated natural and/or translational animal models in drug discovery.
Mike Bishop joined Transpharmation in 2022 following a career that has taken him across the globe from Europe and Africa to North America. Never afraid to make a bold move, Mike is now responsible for all European revenue streams as well as HR, IT and Facilities.
Recognised for his services to leadership development at the Royal Military Academy Sandhurst by the late Queen Elizabeth II in her last Jubilee Honours, Mike is passionate about investing in and developing people to ensure they realise their maximum potential within any organisation.
Dr. Hutcheson, is a highly experience pharmaceutical executive having held several senior positions in the pharmaceutical industry including contract research companies in Europe, Asia and the Unites States.
Most recently he has led portfolio strategy functions as advisor to Chief Scientific Officers including leading asset due-diligence, completed in-licensing partnerships for small molecules and long acting-injectable drug-delivery technology, partnering and alliance-management as well as outsourcing and grants-management.
His early research focused on animal models of central nervous system disorders leveraging his PhD in the behavioral pharmacology of Substance Use Disorder. He has led drug development programs for the treatment of Substance Use Disorder, and for psychiatric disease.
John joined Transpharmation in 2024 as CFO and brings significant experience leading multi-national organizations in both the Pharmaceutical development and manufacturing space as well as the Consumer Package Goods sectors serving in both executive and board roles.
John has supported and led organizations from start-up to exit and brings a pragmatic management style to help organizations develop high-performing teams across all areas of the business and unlock long-term value through sustainable growth and profitability.